AL101 Responders Had Significantly Improved Survival. Ayala Pharmaceuticals presented data from the Phase 2 ACCURACY trial testing AL101 in recurrent or metastatic adenoid cystic carcinoma (ACC), a rare tumor of the secretory glands. AL101 is an inhibitor of gamma secretase, an enzyme that activates the NOTCH signaling pathway. Tumors that have mutations in the NOTCH pathway are associated with a more aggressive course of disease and poor outcomes. About 20% of the ACC tumors have NOTCH mutations.Data Included High and Low Dose Cohorts. The presentation included a data update from the first cohort receiving the low dose (4mg) and the second cohort receiving the high dose (6mg). The study enrolled 87 patients, with 77 evaluable. The 4mg cohort showed a 70.7% disease control rate, with 56% showing evidence of tumor regression. There were 6 (14.6%) partial responses and 23 (56.1%) with stable disease. The 6mg cohort showed 66.7% disease control, with 36% showing evidence of tumor regression. In this group, 3 (8.8%) patients showed partial responses and 21 (58.3%) showed stable disease. Read More >>